These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29109911)

  • 81. Splenectomy via the posterolateral approach in ovarian cancer.
    Xiang L; Chen Y; Liu Y; Huang Z; Zang R
    Int J Gynecol Cancer; 2023 Aug; 33(8):1320-1321. PubMed ID: 37169393
    [No Abstract]   [Full Text] [Related]  

  • 82. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
    Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
    N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
    [TBL] [Abstract][Full Text] [Related]  

  • 83. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
    Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
    [TBL] [Abstract][Full Text] [Related]  

  • 84. MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer.
    Yin S; Yang L; Zheng Y; Zang R
    J Ovarian Res; 2022 May; 15(1):56. PubMed ID: 35538489
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    Shi T; Xiang L; Zhu J; Liu J; Zhang P; Wang H; Feng Y; Zhu T; Zhang Y; Yu A; Jiang W; Wang X; Zhu Y; Wu S; Teng Y; Zhang J; Jiang R; Zhang W; Jia H; Zang R
    J Gynecol Oncol; 2022 Jul; 33(4):e63. PubMed ID: 35775688
    [No Abstract]   [Full Text] [Related]  

  • 86. Correction: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer.
    Yin S; Yang L; Zheng Y; Zang R
    J Ovarian Res; 2022 Jul; 15(1):82. PubMed ID: 35821053
    [No Abstract]   [Full Text] [Related]  

  • 87. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
    Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
    Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Establishment of a mouse model for ovarian cancer-associated venous thromboembolism.
    Ma S; Yin S; Zheng Y; Zang R
    Exp Biol Med (Maywood); 2023 Jan; 248(1):26-35. PubMed ID: 36036485
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Resection of metastatic ovarian cancer in the supragastric lesser sac in 10 steps.
    Xiang L; Chen Y; Shen L; Huang Z; Zang R
    Int J Gynecol Cancer; 2023 Feb; 33(2):308-309. PubMed ID: 36253004
    [No Abstract]   [Full Text] [Related]  

  • 90. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Shi T; Jiang R; Yu J; Yang H; Tu D; Dai Z; Shen Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2018 Jul; 119(1):12-18. PubMed ID: 29899395
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The anatomical structure of the paravesico-vaginal space, a novel landmark for nerve-sparing radical hysterectomy.
    Yin S; Ma SN; Zang RY
    Int J Gynecol Cancer; 2019 Feb; 29(2):441-442. PubMed ID: 30659033
    [No Abstract]   [Full Text] [Related]  

  • 92. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Shi T; Jiang R; Pu H; Yang H; Tu D; Dai Z; Cai Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2019 Aug; 121(5):425-428. PubMed ID: 31383985
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
    Zang R; Zhu J
    J Gynecol Oncol; 2019 Nov; 30(6):e116. PubMed ID: 31576701
    [No Abstract]   [Full Text] [Related]  

  • 94. An improved nerve-sparing radical hysterectomy technique for cervical cancer using the paravesico-vaginal space as a new surgical landmark.
    Zhang Y; Shi T; Yin S; Ma S; Shi D; Guan J; Xiang L; Liu Y; Ren Y; Tan D; Zang R
    Oncotarget; 2017 Oct; 8(52):90413-90420. PubMed ID: 29163840
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cancer-Associated Fibroblast-Derived Interleukin-8 Promotes Ovarian Cancer Cell Stemness and Malignancy Through the Notch3-Mediated Signaling.
    Ji Z; Tian W; Gao W; Zang R; Wang H; Yang G
    Front Cell Dev Biol; 2021; 9():684505. PubMed ID: 34277625
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Gao Q; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Low J; Kong B; Rozita AM; Sen LC; Yin R; Xie X; Liu J; Sun W; Su J; Zhang C; Zang R; Ma D
    Clin Cancer Res; 2022 Jun; 28(11):2278-2285. PubMed ID: 35131903
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.
    Hu D; Guo E; Yang B; Qin X; Fu Y; Fan J; Zhuang X; Yao Q; Lu F; Li W; Xiao R; Wu X; Yang X; Wang Z; Liu C; You L; Zang R; Zhou Q; Zhao W; Chen G; Sun C
    Cancer Sci; 2022 Aug; 113(8):2849-2861. PubMed ID: 35661486
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Investigation of the Potential Mechanisms Underlying Nuclear F-Actin Organization in Ovarian Cancer Cells by High-Throughput Screening in Combination With Deep Learning.
    Wu W; Xing X; Wang M; Feng Y; Wietek N; Chong K; El-Sahhar S; Ahmed AA; Zang R; Zheng Y
    Front Cell Dev Biol; 2022; 10():869531. PubMed ID: 35693931
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
    Vergote I; Gonzalez-Martin A; Lorusso D; Gourley C; Mirza MR; Kurtz JE; Okamoto A; Moore K; Kridelka F; McNeish I; Reuss A; Votan B; du Bois A; Mahner S; Ray-Coquard I; Kohn EC; Berek JS; Tan DSP; Colombo N; Zang R; Concin N; O'Donnell D; Rauh-Hain A; Herrington CS; Marth C; Poveda A; Fujiwara K; Stuart GCE; Oza AM; Bookman MA;
    Lancet Oncol; 2022 Aug; 23(8):e374-e384. PubMed ID: 35901833
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial.
    Xiang L; Shen L; Chen Y; Guo Y; Jiang R; Zhang W; Jia H; Wu Z; Zang R
    BJOG; 2022 Nov; 129 Suppl 2():32-39. PubMed ID: 36485070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.